ClearPoint Neuro Reports First Quarter 2024 Results
ClearPoint Neuro Reports First Quarter 2024 Results
ClearPoint Neuro Reports First Quarter 2024 Results
ClearPoint Neuro公布2024年第一季度业绩
May 07, 2024 4:05pm EDT Download as PDF
美国东部时间 2024 年 5 月 7 日下午 4:05 以 PDF 格式下载
First Quarter Revenue Growth +41%; Record Revenue Achieved
第一季度收入增长+41％；实现创纪录的收入
SOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024.
加利福尼亚州索拉纳海滩，2024年5月7日（GLOBE NEWSWIRE）——提供大脑和脊柱精确导航的全球设备、细胞和基因疗法支持公司ClearPoint Neuro, Inc.（纳斯达克股票代码：CLPT）（“公司”）今天公布了截至2024年3月31日的第一季度财务业绩。
First Quarter Highlights
第一季度亮点
- Reported quarterly revenue of $7.6 million, a 41% year-over-year increase;
- Increased biologics and drug delivery revenue to $4.3 million, a 61% year-over-year increase;
- Partner PTC Therapeutics submitted first-ever neuro gene therapy BLA to the FDA;
- Received 510(k) clearance for SmartFrame OR Stereotactic System to support expansion into the Operating Room and performed first clinical cases;
- Activated eight new hospital customers in the first quarter, a new Company record for a quarter and bringing our total number of global centers to over 80 sites;
- Operational cash burn reduced to $3.8 million, a 32% year-over-year decrease;
- Completed a public offering of common stock, resulting in net proceeds of approximately $16.2 million;
- Cash and cash equivalents totaled $35.4 million as of March 31, 2024.
- 报告的季度收入为760万美元，同比增长41％；
- 生物制剂和药物递送收入增加到430万美元，同比增长61％；
- 合作伙伴PTC Therapeutics向美国食品药品管理局提交了有史以来第一份神经基因疗法BLA；
- 获得了 SmartFrame OR 的 510 (k) 个许可 立体定位系统支持手术室的扩建和首批临床病例；
- 第一季度激活了八个新医院客户，创下了公司一个季度的新纪录，使我们的全球中心总数达到80多个地点；
- 运营现金消耗减少至380万美元，同比下降32％；
- 完成普通股的公开发行，净收益约为1,620万美元；
- 截至2024年3月31日，现金及现金等价物总额为3540万美元。
"Our ClearPoint Neuro team enjoyed the best operating performance in our Company's history, with contributions coming from all four of our growth pillars," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Overall, the company achieved record revenue of $7.6 million or 41% growth, led by 61% growth in biologics and drug delivery revenue, and 255% growth in capital sales and service, which were also both new records. We were thrilled to see not only over 60% growth in the core biologics business, but to see many of our partners progress from a regulatory standpoint including the first neuro gene therapy BLA ever submitted to the FDA, and first patient enrolled in multiple partner IDE trials since the start of the year."
ClearPoint Neuro总裁兼首席执行官乔·伯内特评论说：“我们的ClearPoint Neuro团队创下了公司历史上最好的经营业绩，其贡献来自我们的所有四个增长支柱。”“总体而言，该公司实现了创纪录的760万美元收入，增长了41％，其中生物制剂和药物递送收入增长了61％，资本销售和服务增长了255％，这也是新纪录。我们很高兴看到核心生物制剂业务的增长不仅超过60％，而且看到我们的许多合作伙伴从监管角度取得进展，包括有史以来向FDA提交的第一份神经基因疗法BLA，以及自年初以来首次注册参与多个合作伙伴IDE试验的患者。”
"Our device business activated eight new sites in the quarter," continued Burnett, "which was our fastest activation period ever. For perspective, historically our Company would activate about eight new customers in a calendar year, and here we activated eight in the first quarter alone, with a very healthy funnel of additional activations expected this year. These new sites are going through training and are expected to support our case volume and disposable revenue growth starting in the second quarter, both using our legacy MRI guided navigation system as well as our new FDA cleared Operating Room Navigation system, the SmartFrame OR, for which we initiated a limited market release in Q1 and successfully performed our initial clinical cases. We have also placed multiple new Prism laser therapy systems and so far this year released a new software version to improve workflow and performance. We also achieved FDA clearance of a key ancillary bone anchor which will facilitate laser applicators being placed not only with ClearPoint navigation, but with other common operating room navigation and robotic systems. ClearPoint Neuro's first quarter accomplishments were achieved while keeping our operating expenses relatively flat year over year and reducing our operational cash burn by more than 30%. Our successful capital raise of $16.2 million in net proceeds not only brought new institutional investors into our Company, but also solidified our balance sheet with $35.4 million in cash and cash equivalents at the end of the quarter. The team is excited to have started 2024 off strong with many more important milestones expected this year."
伯内特继续说：“我们的设备业务在本季度激活了八个新站点，这是我们有史以来最快的激活期。从长远来看，我们公司将在一个日历年内激活大约八个新客户，而仅在第一季度我们就激活了八个新客户，预计今年还会有非常不错的额外激活渠道。这些新机构正在接受培训，预计将从第二季度开始支持我们的病例数量和可支配收入的增长，这两个系统均使用我们传统的核磁共振成像制导导航系统以及经美国食品药品管理局批准的新手术室导航系统SmartFrame OR，我们在第一季度启动了限量上市并成功进行了初步临床病例。我们还部署了多个新的Prism激光治疗系统，今年到目前为止，我们还发布了新的软件版本，以改善工作流程和性能。我们还获得了美国食品药品管理局对关键辅助骨锚的批准，这将有助于放置激光涂抹器，不仅可以通过 ClearPoint 导航，还可以与其他常见的手术室导航和机器人系统一起放置。ClearPoint Neuro在第一季度取得的成就的同时，我们的运营支出同比保持相对平稳，运营现金消耗减少了30％以上。我们成功筹集了1,620万澳元的净收益，这不仅为我们公司带来了新的机构投资者，而且在本季度末以3540万美元的现金和现金等价物巩固了我们的资产负债表。该团队很高兴在2024年开局表现强劲，预计今年还会有更多重要的里程碑。”
Business Outlook
商业展望
The Company reaffirms its full year 2024 revenue outlook of between $28.0 and $32.0 million.
该公司重申其2024年全年收入展望在2,800万美元至3,200万美元之间。
Financial Results – Quarter Ended March 31, 2024
财务业绩——截至2024年3月31日的季度
Total revenue was $7.6 million for the three months ended March 31, 2024, and $5.4 million for the three months ended March 31, 2023, which represents an increase of $2.2 million, or 41%.
截至2024年3月31日的三个月，总收入为760万美元，截至2023年3月31日的三个月，总收入为540万美元，增长了220万美元，增长了41％。
Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored pre-clinical and clinical trials utilizing our products, increased 61% to $4.3 million for the three months ended March 31, 2024, from $2.7 million for the same period in 2023.
截至2024年3月31日的三个月，生物制剂和药物递送收入，包括与客户赞助的使用我们产品的临床前和临床试验相关的一次性产品和服务的销售，从2023年同期的270万美元增长了61％，至430万美元。
Functional neurosurgery navigation and therapy revenue, decreased 18% to $1.9 million for the three months ended March 31, 2024, from $2.4 million for the same period in 2023. The decrease is driven primarily by lower service revenue of $0.5 million as a result of pausing a co-development program with one of our Brain Computer Interface partners.
功能性神经外科导航和治疗收入从2023年同期的240万美元下降了18％，至截至2024年3月31日的三个月的190万美元。下降的主要原因是暂停了与我们的一个大脑计算机接口合作伙伴的共同开发计划，导致服务收入减少了50万美元。
Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, increased 255% to $1.4 million for the three months ended March 31, 2024, from $0.4 million for the same period in 2023 due to a large increase in the placements of ClearPoint navigation capital and software and Prism laser units.
资本设备和软件收入，包括ClearPoint可重复使用的硬件和软件以及相关服务的销售，从2023年同期的40万美元增长了255％，至140万美元，这要归因于ClearPoint导航资本和软件以及Prism激光装置的投放量大幅增加。
Gross margin for the three months ended March 31, 2024, was 59%, in line with gross margin of 59% for the three months ended March 31, 2023.
截至2024年3月31日的三个月，毛利率为59％，与截至2023年3月31日的三个月的毛利率为59％。
Operating expenses for the first quarter of 2024 were $8.8 million, compared to $8.9 million for the first quarter of 2023. The decrease was mainly driven by lower product development costs and bad debt expense, partially offset by higher sales and marketing personnel expense.
2024年第一季度的运营支出为880万美元，而2023年第一季度的运营支出为890万美元。下降的主要原因是产品开发成本和坏账支出降低，部分被销售和营销人员支出的增加所抵消。
At March 31, 2024, the Company had cash and cash equivalents totaling $35.4 million as compared to $23.1 million at December 31, 2023, with the increase resulting from the net proceeds from the public offering of common stock of $16.2 million, partially offset by the use of cash in operating activities of $3.8 million.
截至2024年3月31日，该公司的现金及现金等价物总额为3540万美元，而截至2023年12月31日为2310万美元，这一增长来自普通股公开发行净收益1,620万美元，部分被经营活动中使用的现金380万美元所抵消。
Teleconference Information
电话会议信息
Investors and analysts are invited to listen to a live broadcast review of the Company's 2024 first quarter on Tuesday, May 7, 2024 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=8hsthhLn. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
邀请投资者和分析师于美国东部时间2024年5月7日星期二下午4点30分（太平洋时间下午1点30分）收听公司2024年第一季度的直播回顾，该评论可在此处在线观看：https://event.choruscall.com/mediaframe/webcast.html?webcastid=8hsthhLn。想通过电话参加电话会议的投资者和分析师可以拨打 (877) 407-9034，如果来自美国或加拿大以外的国家，则可致电 (201) 493-6737。
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until June 7, 2024, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com/.
对于那些无法观看直播的人，将在电话会议结束后不久进行重播，直至2024年6月7日，如果从美国或加拿大境外拨打电话，请致电（877）660-6853或（201）612-7415，然后输入会议身份证号码413671。该广播的在线档案将在公司的投资者网站上公布，网址为 https://ir.clearpointneuro.com/。
About ClearPoint Neuro
ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
ClearPoint Neuro是一家支持设备、细胞和基因疗法的公司，为大脑和脊柱提供精确导航。该公司以独特的方式为受控药物和器械交付提供成熟的临床产品和临床前开发服务。该公司的旗舰产品ClearPoint神经导航系统已获得美国食品药品管理局的许可，并获得了CE认证。ClearPoint Neuro与北美、欧洲、亚洲和南美的医疗保健和研究中心合作。该公司还与最具创新性的制药/生物技术公司、学术中心和合同研究组织合作，为全球临床前研究和临床试验中直接提供中枢神经系统疗法的解决方案。迄今为止，公司的现场临床专家团队已经进行了数千例手术并提供了支持，该团队为我们在全球的客户和合作伙伴提供支持和服务。欲了解更多信息，请访问 www.clearpointneuro.com。
Forward-Looking Statements
前瞻性陈述
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, the Company's expectation for revenues, operating expenses, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which has been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2024, which the Company intends to file with the Securities and Exchange Commission on or before May 15, 2024. The Company does not assume any obligation to update these forward-looking statements.
本新闻稿和上述电话会议中有关公司计划、增长和战略的声明可能包括联邦证券法背景下的前瞻性陈述。根据这些法律的定义，有关公司未来事件、发展和未来业绩、总潜在市场规模或公司产品和服务的市场机会、公司对收入、运营支出、支持运营和履行未来义务的现金和现金等价物余额的充足性，以及管理层对未来的预期、信念、计划、估计或预测的陈述均为前瞻性陈述。这些前瞻性陈述基于管理层当前的预期，受业务固有风险的影响，这可能导致公司的实际业绩与前瞻性陈述中表达或暗示的业绩存在重大差异。特定的不确定性和风险包括：全球和政治不稳定、供应链中断、劳动力短缺以及宏观经济和通货膨胀状况；公司产品和服务销售的未来收入；公司对公司提供的新产品和服务进行营销、商业化和获得更广泛市场接受的能力；我们的生物制剂和药物交付合作伙伴取得商业成功的能力，包括他们在交付过程中使用公司的产品和服务疗法；公司对支出、未来收入、资本需求以及额外融资的可用性和需求的预期、预测和估计；公司获得额外资金以支持其研发计划的能力；公司管理业务增长的能力；公司吸引和留住关键员工的能力；以及新产品的研究、开发和监管批准所固有的风险。有关这些因素以及可能影响公司实际业绩的其他因素的更多详细信息，请参阅公司向美国证券交易委员会提交的截至2023年12月31日止年度的10-K表年度报告的 “风险因素” 部分，以及公司打算在2024年5月15日当天或之前向美国证券交易委员会提交的截至2024年3月31日的三个月的10-Q表季度报告。公司不承担任何更新这些前瞻性陈述的义务。
| CLEARPOINT NEURO, INC. Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share data) | |||||||
| For The Three Months Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Revenue: | |||||||
| Product revenue | $ | 3,635 | $ | 2,630 | |||
| Service and other revenue | 4,004 | 2,803 | |||||
| Total revenue | 7,639 | 5,433 | |||||
| Cost of revenue | 3,114 | 2,231 | |||||
| Gross profit | 4,525 | 3,202 | |||||
| Research and development costs | 2,625 | 3,023 | |||||
| Sales and marketing expenses | 3,290 | 2,933 | |||||
| General and administrative expenses | 2,841 | 2,958 | |||||
| Operating loss | (4,231) | (5,712) | |||||
| Other expense: | |||||||
| Other expense, net | (26) | (11) | |||||
| Interest income, net | 111 | 114 | |||||
| Net loss | $ | (4,146) | $ | (5,609) | |||
| Net loss per share attributable to common stockholders: | |||||||
| Basic and diluted | $ | (0.16) | $ | (0.23) | |||
| Weighted average shares used in computing net loss per share: | |||||||
| Basic and diluted | 25,452,096 | 24,583,163 | |||||
| CLEARPOINT NEURO, INC. 合并运营报表 （未经审计） （以千计，股票和每股数据除外） | |||||||
| 在结束的三个月中 3月31日 | |||||||
| 2024 | 2023 | ||||||
| 收入： | |||||||
| 产品收入 | $ | 3,635 | $ | 2,630 | |||
| 服务和其他收入 | 4,004 | 2,803 | |||||
| 总收入 | 7,639 | 5,433 | |||||
| 收入成本 | 3,114 | 2,231 | |||||
| 毛利 | 4,525 | 3,202 | |||||
| 研究和开发成本 | 2,625 | 3,023 | |||||
| 销售和营销费用 | 3,290 | 2,933 | |||||
| 一般和管理费用 | 2,841 | 2,958 | |||||
| 营业亏损 | (4,231) | (5,712) | |||||
| 其他费用： | |||||||
| 其他费用，净额 | (26) | (11) | |||||
| 净利息收入 | 111 | 114 | |||||
| 净亏损 | $ | (4,146) | $ | (5,609) | |||
| 归属于普通股股东的每股净亏损： | |||||||
| 基本款和稀释版 | $ | (0.16) | $ | (0.23) | |||
| 用于计算每股净亏损的加权平均股数： | |||||||
| 基本款和稀释版 | 25,452,096 | 24,583,163 | |||||
| CLEARPOINT NEURO, INC. Consolidated Balance Sheets (in thousands, except for share and per share data) | |||||||
| March 31, 2024 | December 31, 2023 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 35,353 | $ | 23,140 | |||
| Accounts receivable, net | 2,511 | 3,211 | |||||
| Inventory, net | 7,960 | 7,911 | |||||
| Prepaid expenses and other current assets | 1,746 | 1,910 | |||||
| Total current assets | 47,570 | 36,172 | |||||
| Property and equipment, net | 1,347 | 1,389 | |||||
| Operating lease, right-of-use assets | 3,447 | 3,564 | |||||
| Software license inventory | 237 | 386 | |||||
| Licensing rights | 887 | 1,041 | |||||
| Other assets | 149 | 109 | |||||
| Total assets | $ | 53,637 | $ | 42,661 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 844 | $ | 393 | |||
| Accrued compensation | 1,634 | 2,947 | |||||
| Other accrued liabilities | 986 | 1,053 | |||||
| Operating lease liabilities, current portion | 497 | 424 | |||||
| Deferred product and service revenue, current portion | 1,232 | 2,613 | |||||
| 2020 senior secured convertible note payable, net | 9,964 | — | |||||
| Total current liabilities | 15,157 | 7,430 | |||||
| Operating lease liabilities, net of current portion | 3,438 | 3,568 | |||||
| Deferred product and service revenue, net of current portion | 458 | 541 | |||||
| 2020 senior secured convertible note payable, net | — | 9,949 | |||||
| Total liabilities | 19,053 | 21,488 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023 | — | — | |||||
| Common stock, $0.01 par value; 90,000,000 shares authorized at March 31, 2024 and December 31, 2023; 27,416,345 shares issued and outstanding at March 31, 2024; and 24,652,729 issued and outstanding at December 31, 2023 | 274 | 247 | |||||
| Additional paid-in capital | 210,912 | 193,382 | |||||
| Accumulated deficit | (176,602) | (172,456) | |||||
| Total stockholders' equity | 34,584 | 21,173 | |||||
| Total liabilities and stockholders' equity | $ | 53,637 | $ | 42,661 | |||
| CLEARPOINT NEURO, INC. 合并资产负债表 （以千计，股票和每股数据除外） | |||||||
| 三月三十一日 2024 | 12月31日 2023 | ||||||
| （未经审计） | |||||||
| 资产 | |||||||
| 流动资产： | |||||||
| 现金和现金等价物 | $ | 35,353 | $ | 23,140 | |||
| 应收账款，净额 | 2,511 | 3,211 | |||||
| 库存，净额 | 7,960 | 7,911 | |||||
| 预付费用和其他流动资产 | 1,746 | 1,910 | |||||
| 流动资产总额 | 47,570 | 36,172 | |||||
| 财产和设备，净额 | 1,347 | 1,389 | |||||
| 经营租赁、使用权资产 | 3,447 | 3,564 | |||||
| 软件许可证清单 | 237 | 386 | |||||
| 许可权 | 887 | 1,041 | |||||
| 其他资产 | 149 | 109 | |||||
| 总资产 | $ | 53,637 | $ | 42,661 | |||
| 负债和股东权益 | |||||||
| 流动负债： | |||||||
| 应付账款 | $ | 844 | $ | 393 | |||
| 应计补偿 | 1,634 | 2,947 | |||||
| 其他应计负债 | 986 | 1,053 | |||||
| 经营租赁负债，流动部分 | 497 | 424 | |||||
| 递延产品和服务收入，当期部分 | 1,232 | 2,613 | |||||
| 2020年优先有担保可转换票据应付票据，净额 | 9,964 | — | |||||
| 流动负债总额 | 15,157 | 7,430 | |||||
| 经营租赁负债，扣除流动部分 | 3,438 | 3,568 | |||||
| 递延产品和服务收入，扣除当期部分 | 458 | 541 | |||||
| 2020年优先有担保可转换票据应付票据，净额 | — | 9,949 | |||||
| 负债总额 | 19,053 | 21,488 | |||||
| 承付款和意外开支 | |||||||
| 股东权益： | |||||||
| 优先股，面值0.01美元；授权2500万股；截至2024年3月31日和2023年12月31日，未发行和流通股票 | — | — | |||||
| 普通股，面值0.01美元；截至2024年3月31日和2023年12月31日授权的9,000,000股股票；截至2024年3月31日已发行和流通的27,416,345股股票；截至2023年12月31日已发行和流通的24,652,729股 | 274 | 247 | |||||
| 额外的实收资本 | 210,912 | 193,382 | |||||
| 累计赤字 | (176,602) | (172,456) | |||||
| 股东权益总额 | 34,584 | 21,173 | |||||
| 负债和股东权益总额 | $ | 53,637 | $ | 42,661 | |||
| CLEARPOINT NEURO, INC. Consolidated Statements of Cash Flows (Unaudited) (in thousands) | |||||||
| For The Three Months Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (4,146) | $ | (5,609) | |||
| Adjustments to reconcile net loss to net cash flows from operating activities: | |||||||
| Allowance for credit losses (recoveries) | (146) | 171 | |||||
| Depreciation and amortization | 243 | 129 | |||||
| Share-based compensation | 1,504 | 1,307 | |||||
| Amortization of debt issuance costs and original issue discounts | 15 | 14 | |||||
| Amortization of lease right-of-use, net of accretion in lease liabilities | 231 | 142 | |||||
| Accretion of discounts on short-term investments | — | (69) | |||||
| Increase (decrease) in cash resulting from changes in: | |||||||
| Accounts receivable | 846 | (184) | |||||
| Inventory, net | 53 | (578) | |||||
| Prepaid expenses and other current assets | 165 | (42) | |||||
| Other assets | (39) | — | |||||
| Accounts payable and accrued expenses | (931) | (959) | |||||
| Lease liabilities | (171) | (146) | |||||
| Deferred revenue | (1,464) | 144 | |||||
| Net cash flows from operating activities | (3,840) | (5,680) | |||||
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | — | (138) | |||||
| Net cash flows from investing activities | — | (138) | |||||
| Cash flows from financing activities: | |||||||
| Proceeds from public offering of common stock, net of offering costs | 16,183 | — | |||||
| Proceeds from stock option exercises | 21 | — | |||||
| Payments for taxes related to net share settlement of equity awards | (151) | (5) | |||||
| Net cash flows from financing activities | 16,053 | (5) | |||||
| Net change in cash and cash equivalents | 12,213 | (5,823) | |||||
| Cash and cash equivalents, beginning of period | 23,140 | 27,615 | |||||
| Cash and cash equivalents, end of period | $ | 35,353 | $ | 21,792 | |||
| SUPPLEMENTAL CASH FLOW INFORMATION | |||||||
| Cash paid for: | |||||||
| Income taxes | $ | — | $ | — | |||
| Interest | $ | 185 | $ | 179 | |||
| CLEARPOINT NEURO, INC. 合并现金流量表 （未经审计） （以千计） | |||||||
| 在结束的三个月中 3月31日 | |||||||
| 2024 | 2023 | ||||||
| 来自经营活动的现金流： | |||||||
| 净亏损 | $ | (4,146) | $ | (5,609) | |||
| 为协调净亏损与经营活动产生的净现金流而进行的调整： | |||||||
| 信贷损失备抵金（追回款） | (146) | 171 | |||||
| 折旧和摊销 | 243 | 129 | |||||
| 基于股份的薪酬 | 1,504 | 1,307 | |||||
| 债券发行成本和原始发行折扣的摊销 | 15 | 14 | |||||
| 租赁使用权的摊销，扣除租赁负债的增加 | 231 | 142 | |||||
| 增加短期投资折扣 | — | (69) | |||||
| 以下变动导致的现金增加（减少）： | |||||||
| 应收账款 | 846 | (184) | |||||
| 库存，净额 | 53 | (578) | |||||
| 预付费用和其他流动资产 | 165 | (42) | |||||
| 其他资产 | (39) | — | |||||
| 应付账款和应计费用 | (931) | (959) | |||||
| 租赁负债 | (171) | (146) | |||||
| 递延收入 | (1,464) | 144 | |||||
| 来自经营活动的净现金流量 | (3,840) | (5,680) | |||||
| 来自投资活动的现金流： | |||||||
| 购买财产和设备 | — | (138) | |||||
| 来自投资活动的净现金流量 | — | (138) | |||||
| 来自融资活动的现金流： | |||||||
| 公开发行普通股的收益，扣除发行成本 | 16,183 | — | |||||
| 股票期权行使的收益 | 21 | — | |||||
| 支付与股权奖励净股结算相关的税款 | (151) | (5) | |||||
| 来自融资活动的净现金流量 | 16,053 | (5) | |||||
| 现金和现金等价物的净变化 | 12,213 | (5,823) | |||||
| 现金和现金等价物，期初 | 23,140 | 27,615 | |||||
| 现金和现金等价物，期末 | $ | 35,353 | $ | 21,792 | |||
| 补充现金流信息 | |||||||
| 已支付的现金用于： | |||||||
| 所得税 | $ | — | $ | — | |||
| 利息 | $ | 185 | $ | 179 | |||
Contact: Media Contact: Jacqueline Keller, Vice President of Marketing (888) 287-9109 ext. 4 info@clearpointneuro.com Investor Relations: Danilo D'Alessandro, Chief Financial Officer (888) 287-9109 ext. 3 ir@clearpointneuro.com
联系人：媒体联系人：杰奎琳·凯勒，营销副总裁 (888) 287-9109 分机 4 info@clearpointneuro.com 投资者关系：达尼洛·达莱桑德罗，首席财务官 (888) 287-9109 分机 3 ir@clearpointneuro.com
Released May 7, 2024
2024 年 5 月 7 日发布
译文内容由第三方软件翻译。